Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.
Phase:
PHASE3
Details
Lead Sponsor:
Xinqiao Hospital of Chongqing
Collaborators:
The First Affiliated Hospital of Hainan Medical College The First Affiliated Hospital of Nanchang University